GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
IPSCs for off-the-shelf therapies? #stemcells #cancer
Eric Topol on Twitter
“"Universal" induced pluripotent stem cell therapy? A clinical trial in #cancer is underway https://t.co/GKvY80TZ94 @CellPressNews by @Catalytic...
GAiT and collaborators (ISCT, CIRM, HESI CT-TRACS & ISCBI) will host a series of Expert Panels on topics pertinant to the manufacture of human Pluripotent Stem Cells 30 JUNE 2019 in L.A. The event will be live-streamed & also edited recordings will be posted on our websites
GAiT will have multiple speakers at this event in September 2019
Phacilitate on Twitter
“Early Bird tickets are now available for #PLE2019! Register your place today: https://t.co/f3l7j5yv3I #europe #advancedtherapies #celltherapy...
It was GAiT's honour to describe rationale for, & design of, the iPSC Quality Round 2019 at #ISCT2019, listing all Organizers and Participants. We are grateful to @ISCTglobal (International Society for Cell and Gene Therapy) for allowing us describe this important initiative.
Defining, and testing for, quality of iPS cells at #ISCT2019. This morning discussed in the context of animal and pre-clinical studies.
Verifying induced pluripotent stem cell lines are the starting material needed for allogeneic therapeutic development. GAiT will be speaking about the iPSC Quality Round 2019 at the Plenary Hall at #ISCT2019 today 15.45 AEST.
Register for Pluripotent Stem Cell Manufacturing - Expert Panel Discussion 30 JUNE 2019
Pluripotent Stem Cell Manufacturing Meeting - Expert Panel Discussion
Pluripotent Stem Cell Manufacturing Meeting 2019